Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma

Conclusion: Pazopanib is a promising therapeutic option in patients with HEH.
Source: Clinical Sarcoma Research - Category: Cancer & Oncology Source Type: research